An antibody–drug conjugate (Trodelvy): a humanized anti–TROP‑2 monoclonal antibody linked to SN‑38 (active metabolite of irinotecan), a topoisomerase I inhibitor. After binding TROP‑2 on tumor cells, it is internalized and releases SN‑38 to induce DNA damage and apoptosis with a bystander effect.
Humanized anti–TROP-2 monoclonal antibody linked to SN-38 (topoisomerase I inhibitor). After binding TROP-2 on tumor cells, the ADC is internalized and cleaved to release SN-38, which stabilizes topo I–DNA complexes, causing DNA breaks, inhibition of DNA replication, and apoptosis, with a bystander killing effect.
The anti–TROP-2 antibody–drug conjugate binds TROP-2, is internalized, and releases SN-38 (a topoisomerase I inhibitor) that causes DNA damage/replication arrest and apoptosis in target-expressing cells, with a bystander effect.
Humanized anti-HER2 IgG1 monoclonal antibody that inhibits HER2/ERBB2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody against HER2/ERBB2 that binds HER2 on tumor cells, inhibits HER2 signaling and receptor dimerization to suppress proliferation, and engages Fc receptors to mediate antibody-dependent cellular cytotoxicity (ADCC), with possible complement-dependent cytotoxicity, in HER2-overexpressing cancers.
Trastuzumab binds HER2 on target cells and its Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells) to mediate ADCC; it may also trigger complement-dependent cytotoxicity and can induce apoptosis via HER2 signaling blockade.
HER2-targeted bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 dimerization and signaling and inducing ADCC.
Bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 heterodimerization and downstream signaling (e.g., PI3K/AKT/MAPK) and inducing antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
KN026 binds HER2 on tumor cells and engages immune effector cells via its Fc (FcγR on NK cells/macrophages) to induce ADCC (and potentially CDC), leading to target-cell lysis; blockade of HER2 signaling can also promote apoptosis.
HER2-targeted bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 dimerization and signaling and inducing ADCC.
Bispecific IgG1 monoclonal antibody that binds two non-overlapping HER2 epitopes (trastuzumab- and pertuzumab-like), blocking HER2 heterodimerization and downstream signaling (e.g., PI3K/AKT/MAPK) and inducing antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
IgG1 antibody binds HER2 on tumor cells and engages Fcγ receptor–bearing immune effectors (e.g., NK cells, macrophages) to mediate ADCC/ADCP, killing HER2+ cells; also blocks HER2 signaling (cytostatic).
Anti-HER2 IgG1 monoclonal antibody that inhibits HER2 signaling and mediates antibody-dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody that binds the HER2 receptor, blocks receptor dimerization and downstream signaling, and elicits immune-mediated killing of HER2-overexpressing tumor cells via antibody-dependent cellular cytotoxicity (ADCC).
Trastuzumab binds HER2 on target cells and its Fc engages Fcγ receptors on NK cells/other effectors to elicit ADCC (perforin–granzyme); some CDC may contribute.